Task Order 1: The Interventional Agent Development Services Program

任务顺序 1：介入药物开发服务计划

• 批准号: 10704965
• 负责人: JON MIRSALIS
• 金额: $ 0.01万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-05 至 2020-02-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10704965
• 关键词: Chemistry; Communicable Diseases; Contracts; Development; Development Plans; Evaluation; Hypersensitivity skin testing; Image; In Vitro; Interventional Agent Development; Lead; National Institute of Allergy and Infectious Disease; Office of Administrative Management; Services; Toxicology; Toxin; in vivo; in-vivo diagnostics; pathogen; pre-clinical; preclinical development; preclinical safety; programs; reagent testing; service programs; therapeutic development

The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins, such as imaging and skin test reagents. Services include: lead identification and development; chemistry and manufacturing; in vitro and in vivo preclinical safety, toxicology and biokinetics; and preclinical development, planning and evaluation.

介入剂开发服务计划提供服务，以促进临床前开发治疗和新的体内诊断传染病致病病原体和/或毒素，如成像和皮肤测试试剂。服务包括：先导化合物鉴定和开发;化学和制造;体外和体内临床前安全性、毒理学和生物学;以及临床前开发、规划和评价。